We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
26
Alkermes
ALKS
$8.11B
$44.7M 0.25%
1,500,000
– –
CCXI
27
DELISTED
ChemoCentryx, Inc.
CCXI
$44.4M 0.25%
1,792,657
+875,795
+96% +$19.3M
KDNY
28
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$44.3M 0.25%
2,534,102
+200,000
+9% +$3.14M
INSM icon
29
Insmed
INSM
$27.5B
$42.5M 0.24%
2,156,001
– –
IMTX icon
30
Immatics
IMTX
$1.22B
$38.5M 0.22%
4,423,731
– –
DBVT
31
DBV Technologies
DBVT
$914M
$37.3M 0.21%
1,461,426
– –
JBIO
32
Jade Biosciences
JBIO
$1.36B
$32.4M 0.18%
59,143
– –
AMRN
33
Amarin Corp
AMRN
$298M
$31.5M 0.18%
1,058,490
– –
VSTM icon
34
Verastem
VSTM
$624M
$31.3M 0.18%
2,249,075
– –
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$2.55B
$28.1M 0.16%
470,974
+26,530
+6% +$1.63M
TSVT
36
DELISTED
2seventy bio
TSVT
$27.2M 0.15%
2,062,744
– –
KNSA icon
37
Kiniksa Pharmaceuticals
KNSA
$6.17B
$27.1M 0.15%
2,799,577
– –
BMEA icon
38
Biomea Fusion
BMEA
$99.3M
$25.2M 0.14%
2,104,559
+553,114
+36% +$3.24M
ALT icon
39
Altimmune
ALT
$605M
$24.3M 0.14%
2,075,403
+1,003,365
+94% +$6.19M
NVTA
40
DELISTED
Invitae Corporation
NVTA
$24.1M 0.14%
9,873,488
– –
PACB icon
41
Pacific Biosciences
PACB
$420M
$24.1M 0.14%
5,444,963
– –
XENE icon
42
Xenon Pharmaceuticals
XENE
$5.88B
$22.9M 0.13%
751,639
– –
HRTX icon
43
Heron Therapeutics
HRTX
$60.4M
$22.7M 0.13%
8,131,678
– –
MRUS
44
DELISTED
Merus
MRUS
$22.5M 0.13%
995,397
-1,042,072
-51% -$21.8M
VERV
45
DELISTED
Verve Therapeutics
VERV
$21.6M 0.12%
1,416,530
– –
DSGN icon
46
Design Therapeutics
DSGN
$938M
$20.1M 0.11%
1,436,636
– –
AFMD
47
DELISTED
Affimed
AFMD
$18.3M 0.1%
659,683
+144,366
+28% +$4.94M
TIL icon
48
Instil Bio
TIL
$51.4M
$18M 0.1%
194,685
– –
OTIC
49
DELISTED
Otonomy, Inc.
OTIC
$17.5M 0.1%
8,412,634
+567,942
+7% +$1.18M
DNLI icon
50
Denali Therapeutics
DNLI
$3.98B
$17.3M 0.1%
588,738
+500,000
+563% +$13.1M
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2022 Portfolio in Review

As of Q2 2022, Julian Baker held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Julian Baker added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Julian Baker's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Julian Baker fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Julian Baker's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Julian Baker opened 5 new positions and closed 6 in Q2 2022.
  • Julian Baker's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.